BioNTech Pivots to Seoul Data Readout After Colorectal Cancer Trial Collapse

BioNTech halts a Phase 2 colorectal cancer trial, gains FDA approval for updated COVID vaccine, and prepares for key lung cancer data in September.

The arithmetic of drug development rarely looks this stark. In a single week, BioNTech watched a flagship oncology program fall apart, collected a regulatory win for its legacy vaccine business, and set the stage for what could be its most consequential data presentation of the year. The common thread binding those events: a company trying to prove its post-pandemic identity is not defined by one failed study.

The setback came Friday, when the Mainz-based biotech halted a Phase 2 trial of autogene cevumeran, a personalized mRNA cancer immunotherapy developed with Roche's Genentech. An independent data monitoring committee flagged a numerical imbalance in overall survival between treatment arms and concluded that continuing the study would be unlikely to change the outcome. Shares dropped 7.7% on the news, closing at €88.30 — roughly 17% below the 52-week high of €105.80 touched in January. Morgan Stanley weighed in the same day, calling the discontinuation negative for the company.

A Pipeline Wider Than One Failed Study

The colorectal cancer candidate had been viewed as one of the most advanced personalized mRNA oncology programs in the field, which made the halt all the more jarring. Yet the company's broader oncology portfolio tells a more layered story. BioNTech has launched six registrational trials this year, five of them centered on pumitamig, a PD-L1×VEGF-A bispecific immunomodulator that has already produced a third global dataset with consistent efficacy across varying PD-L1 expression levels at the ASCO congress.

Investors now have a concrete date to watch: September 12–15, when the IASLC World Conference on Lung Cancer convenes in Seoul. BioNTech plans to present first-time global clinical data on pumitamig combined with elfetabart drozuntecan, a B7H3-directed antibody-drug conjugate, alongside updated survival figures from the Phase 3 PRESERVE-003 trial of gotistobart. For a pipeline that has yet to show lung cancer data on these newer combinations, the Seoul readout represents the first real test of whether the oncology franchise extends beyond the failed colorectal indication.

Vaccine Business Offers a Counterweight

Some relief arrived from an unexpected corner. The FDA granted approval for Comirnaty XFG, the adapted COVID-19 vaccine formula developed with Pfizer for the 2026/2027 season, targeting the XFG variant. The authorization covers adults 65 and older as well as at-risk groups aged 5 to 64. While vaccine revenue has shrunk dramatically — second-quarter sales fell to €105.6 million from €260.8 million a year earlier — the franchise still provides a stabilizing revenue stream as the oncology pipeline matures unevenly.

That maturation is proving costly in more ways than one. BioNTech trimmed its full-year 2026 revenue guidance to €1.6–1.9 billion, reflecting the continued contraction of pandemic-era demand. But the balance sheet remains a formidable buffer: €16.6 billion in cash and securities, a war chest that could absorb multiple clinical failures without threatening the company's strategic direction.

A Leadership Transition Adds Another Layer

The company is also preparing for a change at the top. Guido Oelkers is slated to succeed Prof. Ugur Sahin as CEO no later than February 1, 2027, a handover that signals BioNTech's intent to institutionalize its second act. The first act was the pandemic — fast, urgent, singular in purpose. The second is oncology: slower, more complex, and defined by parallel bets where attrition is the norm rather than the exception.

The stock's recent trajectory captures the whiplash. On a weekly basis, shares are down 9.0%, trading around €88.15, yet the monthly picture still shows a 12% gain — evidence that Friday's drop was a sharp but contained reaction to a specific clinical event rather than a repricing of the entire investment thesis.

The question hanging over BioNTech now is straightforward: Can pumitamig and the rest of the oncology pipeline generate enough momentum in Seoul to offset the gradual fade of the COVID franchise? The answer won't come from any single trading session. It will emerge over the coming weeks, as the data from the IASLC conference either validates the breadth of the platform or raises further doubts about its clinical reliability.